Preclinical manufacturing strategy and results demonstrating efficacy in a PD rodent model and safety in a 9-month GLP toxicology study are reported.
Abstract
Toward development of an autologous, induced pluripotent stem cell (iPSC)-based cell therapy for Parkinson's disease (PD), we demonstrate successful, reproducible genomic and transcriptomic qualification of patient-derived dopaminergic neuron precursor cells (DANPCs) across multiple donors. Our analysis includes whole-genome sequencing data from fibroblasts, iPSCs, and DANPCs and the development of NeuriTest, an RNAseq-based bioinformatic analysis of DANPCs designed to predict cell quality based on empirical animal data. Autologous cell therapies are immune matched to the patient, potentially augmenting durability of benefit compared to allogeneic cells while negating the need for immunosuppression and accompanying side effects. Patient-specific iPSCs are an autologous cell source that can be differentiated to dopaminergic neurons, the cell type lost in PD. We report here our preclinical manufacturing strategy and results demonstrating efficacy in a PD rodent model and safety in a 9-month GLP toxicology study.
It is proposed that the interval between cell transplantation and long-term engraftment constitutes a biological “black box” in which graft fate and therapeutic outcome are determined, marking a conceptual transition from stem cell biology toward transplantation biology.
Y. Cha, Kwang-Soo Kim· Cell Reports Medicine· 0 citations
This Review evaluates the technological and translational trajectories that have defined the iPSC era and analyzes the operational barriers to therapeutic development, envisioning a paradigm shift in which iPSC-derived interventions transition from bespoke experimental models toward standardized, engineered biological...
Jaecheol Lee, Todd J. Herron, L. Studer et al.· Nature Medicine· 0 citations
This patient-derived iPSC-based model provides a platform for investigating the biological significance of neural lineage-specific eHHV-6 transcripts and may facilitate interpretation of HHV-6 DNA detection in patients with eHHV-6 by enabling studies of cell type-dependent viral transcription.
Hiroki Miura, Tomoki Inagaki, T. Ohye et al.· Journal of Infectious Diseas...· 0 citations
This review traces key field milestones and analyzes prospects and hurdles for next-generation iPSC therapies as autologous and allogeneic iPSC therapies complement each other for distinct clinical demands.
Anmin Wang, Yunpei Zhang, Hong-Kui Deng et al.· Cell Reports Medicine· 0 citations
Background The clinical efficacy of anticancer drugs is often limited by dose-dependent toxicity to normal cells, particularly to rapidly dividing stem and progenitor cell populations. Traditional preclinical toxicity screening relies on animal models or primary human cells/immortalized lines, both of which have signif...
K. Vincze, N. Varga, Szilárd Tóth et al.· Pathology oncology research...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.